Drug reference
ferrous sucrose
Parenteral iron preparation · Haematinic
Parenteral iron preparationHaematinicATC B03AC04
CDSCO approvedATC B03AC04
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
C
FDA category + note
Mechanism
A high molecular weight complex of iron hydroxide with sucrose, taken up by reticuloendothelial cells, where iron dissociates and is utilized.
Indications
Anaemia in kidney disease patientsWhen oral iron is not toleratedFailure to absorb oral iron (malabsorption, inflammatory bowel disease, chronic inflammation)Non-compliance to oral ironSevere deficiency with chronic bleedingAlong with erythropoietin (to meet demands of induced rapid erythropoiesis)
Dosing
- Adult
- 100 mg (max 200 mg) i.v. over 5 min, once daily to once weekly until total calculated dose is administered.
Contraindications
- i.m. or s.c. injection (due to high alkalinity of solution)
- Concurrent oral iron administration (and up to 5 days after last injection)
Side effects
Common
low incidence of hypersensitivity reactionmilder side effects
Serious
- kidney damage
Pregnancy & lactation
Pregnancy
C
Related guidelines
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Iron deficiency anaemia in adults
ICMR · Hematology · 2023
Iron deficiency anaemia in pregnancy
ICMR · Obstetrics & Gynaecology · 2022
Iron deficiency anaemia in pregnancy
FOGSI · Obstetrics & Gynaecology · 2017
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Other Parenteral iron preparation drugs
Ask House about ferrous sucrose
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team